<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572777</url>
  </required_header>
  <id_info>
    <org_study_id>003-08/18-03/0001</org_study_id>
    <nct_id>NCT03572777</nct_id>
  </id_info>
  <brief_title>Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy.</brief_title>
  <official_title>A Randomized Controlled Study: Concomitant Versus Hybrid Therapy in the Treatment of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonio Mestrovic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Split</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Split, School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Split, School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effectiveness of two therapeutic protocols in the&#xD;
      treatment of Helicobacter pylori infection.&#xD;
&#xD;
      The hypothesis of our research is that the two therapeutic options (hybrid and concomitant&#xD;
      therapy) will be equally successful in the treatment of Helicobacter pylori infection. In&#xD;
      other words, in both therapeutic groups we expect successful treatment of Helicobacter pylori&#xD;
      infection in or more than 90 % of patients.&#xD;
&#xD;
      In other studies, both therapeutic options have the same efficacy in treating H. pylori&#xD;
      infection. On the other had there are no studies available in Croatia to compare the&#xD;
      effectiveness of these therapeutic options so far, which is the main objective of our&#xD;
      research. The secondary goals of our study will be: the existence of differences in the&#xD;
      occurrence of possible side effects, as well as the compliance between patients in both&#xD;
      therapeutic options. It is also our aim to compare the quality of life of patients with&#xD;
      Helicobacter pylori infection before and after treatment, via a questionnaire that is common&#xD;
      for this purpose.&#xD;
&#xD;
      The study is expected to include a total of 120 patients (60 patients in each therapy group),&#xD;
      and the planned duration is 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori status one month after treatment.</measure>
    <time_frame>One month after finishing with therapy.</time_frame>
    <description>Helicobacter pylori status (positive or negative), will be measured by stool test, one month after finishing with therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance of patients in both therapy groups in treatment of Helicobacter pylori infection.</measure>
    <time_frame>One month after finishing with therapy.</time_frame>
    <description>Compliance will be measured by counting pills that were taken during therapy. More than or equal 80 % of taken pills will be consider as good compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of therapy in both groups in treatment of Helicobacter pylori infection.</measure>
    <time_frame>One month after finishing with therapy.</time_frame>
    <description>Patients will be ask to report any adverse effect occured during treatment. They will be divided in groups according to degree of limiting daily activities: no adverse effects; mild (no limit of activities); moderate (partially limited activities); severe (completely limited activities).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life before and after eradication therapy</measure>
    <time_frame>One month after therapy</time_frame>
    <description>Quality of life before and after eradication (both groups combined) therapy will be reported by The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. GSRS questionnaire: 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents no discomfort at all, 2 - minor discomfort, 3 -mild discomfort, 4 - moderate discomfort, 5 -moderately severe discomfort, 6 -severe discomfort, 7 - very severe discomfort</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life before and after eradication therapy between hybrid and concomitant group.</measure>
    <time_frame>One month after therapy</time_frame>
    <description>Quality of life before and after eradication therapy will be reported by the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire comparing both groups. GSRS questionnaire: 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents no discomfort at all, 2 - minor discomfort, 3 -mild discomfort, 4 - moderate discomfort, 5 -moderately severe discomfort, 6 -severe discomfort, 7 - very severe discomfort</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Concomitant therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hybrid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concomitant therapy</intervention_name>
    <description>Amoxicillin ('Amoksicilin') 1 g bid 14 days.</description>
    <arm_group_label>Concomitant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concomitant therapy</intervention_name>
    <description>Clarithromycin ('Makcin') 500 mg bid for 14 days</description>
    <arm_group_label>Concomitant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concomitant therapy</intervention_name>
    <description>Metronidazole ('Medazol') 500 mg bid for 14 days</description>
    <arm_group_label>Concomitant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concomitant therapy</intervention_name>
    <description>Esomeprazole ('Emanera') 40 mg bid for 14 days</description>
    <arm_group_label>Concomitant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hybrid therapy</intervention_name>
    <description>Amoxicillin ('Amoksicilin') 1 g bid 14 days</description>
    <arm_group_label>Hybrid therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hybrid therapy</intervention_name>
    <description>Esomeprazole ('Emanera') 40 mg bid for 14 days</description>
    <arm_group_label>Hybrid therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hybrid therapy</intervention_name>
    <description>Clarithromycin ('Makcin') 500 mg bid for the last 7 days</description>
    <arm_group_label>Hybrid therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hybrid therapy</intervention_name>
    <description>Metronidazole ('Medazol') 500 mg bid for the last 7 days</description>
    <arm_group_label>Hybrid therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Helicobacter pylori infection (documented by: positive antigen stool test, or positive&#xD;
             urease rapid test obtained during upper endoscopy, or Helicobacter pylori in&#xD;
             histological finding, or positive C-urea breath test; according to recent Maastricht V&#xD;
             guidelines;&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 18&#xD;
&#xD;
          -  previously treatment of Helicobacter pylori infection&#xD;
&#xD;
          -  malignancy of stomach or other site&#xD;
&#xD;
          -  history of taking proton pump inhibitors, H2 antagonist, bismuth or antibiotics&#xD;
             (amoxicillin, metronidazole, clarithromycin) in previous month&#xD;
&#xD;
          -  significant underlying disease (renal failure, psychiatric disorders)&#xD;
&#xD;
          -  history of allergic reactions to any medications used in study&#xD;
&#xD;
          -  refuse to participate in study&#xD;
&#xD;
          -  breastfeeding and pregnancy&#xD;
&#xD;
          -  quitting the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Meštrović, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Centre Split, Croatia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Centre Split</name>
      <address>
        <city>Split</city>
        <zip>21210</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Split, School of Medicine</investigator_affiliation>
    <investigator_full_name>Antonio Mestrovic</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori, eradication, hybrid therapy, concomitant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

